All In Biotech

Drug Trial Radar · NCT00571675

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Oct 2007

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Ascenta TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

  • AT-101, prednisone and docetaxelDrug

    docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3

  • placebo, prednisone and docetaxelDrug

    docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate and compare the two treatment arms with respect to overall survival (OS)Time frame: 33 months

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    New Port Richey, Florida

  • Site not named

    Ocoee, Florida

  • Site not named

    Fishers, Indiana

  • Site not named

    Burnsville, Minnesota

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Las Cruces, New Mexico

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Kettering, Ohio

  • Site not named

    Eugene, Oregon

  • Site not named

    Spartanburg, South Carolina

  • Site not named

    Amarillo, Texas

  • Site not named

    Arlington, Texas

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Denton, Texas

  • Site not named

    Midland, Texas

  • Site not named

    Paris, Texas

  • Site not named

    Webster, Texas

  • Site not named

    Fairfax, Virginia

  • Site not named

    Norfolk, Virginia

  • Site not named

    Kennewick, Washington

  • Site not named

    Vancouver, Washington

  • Site not named

    Barnaul, Russia

  • Site not named

    Engel's, Russia

  • Site not named

    Kazan', Russia

  • Site not named

    Kursk, Russia

  • Site not named

    Kuzmolovsky, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Sochi, Russia

  • Site not named

    Stavropol, Russia

  • Site not named

    Voronezh, Russia

  • Site not named

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.